These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 10496304)

  • 41. Anti-oncogene ribozymes for cancer gene therapy.
    Irie A; Kijima H; Ohkawa T; Bouffard DY; Suzuki T; Curcio LD; Holm PS; Sassani A; Scanlon KJ
    Adv Pharmacol; 1997; 40():207-57. PubMed ID: 9217927
    [No Abstract]   [Full Text] [Related]  

  • 42. Ribozyme-mediated in vitro cleavage of transcripts arising from the major transforming genes of human papillomavirus type 16.
    Lu D; Chatterjee S; Brar D; Wong KK
    Cancer Gene Ther; 1994 Dec; 1(4):267-77. PubMed ID: 7627817
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ribozymes. Their functions and strategies for their use.
    Gibson SA; Shillitoe EJ
    Mol Biotechnol; 1997 Apr; 7(2):125-37. PubMed ID: 9219227
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapeutic potential of oligonucleotide-based therapy in cardiovascular disease.
    Morishita R; Kaneda Y; Ogihara T
    BioDrugs; 2003; 17(6):383-9. PubMed ID: 14614761
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-oncogene and tumor suppressor gene therapy--examples from a lung cancer animal model.
    Zhang WW; Roth JA
    In Vivo; 1994; 8(5):755-69. PubMed ID: 7727723
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hammerhead ribozymes: biochemical and chemical considerations.
    Goodchild J
    Curr Opin Mol Ther; 2000 Jun; 2(3):272-81. PubMed ID: 11249621
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design and applications of modified oligonucleotides.
    Gallo M; Montserrat JM; Iribarren AM
    Braz J Med Biol Res; 2003 Feb; 36(2):143-51. PubMed ID: 12563516
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Frontiers in nucleic acid-based drug research and development.
    Sun LQ; Wong JP
    Future Med Chem; 2015; 7(13):1619-21. PubMed ID: 26465712
    [No Abstract]   [Full Text] [Related]  

  • 49. Gene Therapy.
    Bauer DE; Kohn DB
    Hematol Oncol Clin North Am; 2017 Oct; 31(5):xiii-xiv. PubMed ID: 28895857
    [No Abstract]   [Full Text] [Related]  

  • 50. Anti-genes: siRNA, ribozymes and antisense.
    Scanlon KJ
    Curr Pharm Biotechnol; 2004 Oct; 5(5):415-20. PubMed ID: 15544489
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ribozymes as therapeutic tools for genetic disease.
    Phylactou LA; Kilpatrick MW; Wood MJ
    Hum Mol Genet; 1998; 7(10):1649-53. PubMed ID: 9735387
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antisense regulation of oncogenes in human cancer.
    Mukhopadhyay T; Roth JA
    Crit Rev Oncog; 1996; 7(3-4):151-90. PubMed ID: 9258601
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Antisense oligonucleotides: a new therapeutic approach].
    Guinot P; Temsamani J
    Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The therapeutic potential of ribozymes.
    James HA; Gibson I
    Blood; 1998 Jan; 91(2):371-82. PubMed ID: 9427689
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is antisense an appropriate nomenclature or design for oligodeoxynucleotides aimed at the inhibition of HIV-1 replication?
    Lavigne C; Yelle J; Sauve G; Thierry AR
    AAPS PharmSci; 2002; 4(2):E9. PubMed ID: 12102618
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics.
    Dobrovolskaia MA; McNeil SE
    Expert Opin Biol Ther; 2015 Jul; 15(7):1023-48. PubMed ID: 26017628
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Making sense of antisense.
    Murakami A
    Trends Mol Med; 2001 Oct; 7(10):430-1. PubMed ID: 11597507
    [No Abstract]   [Full Text] [Related]  

  • 58. Hammerhead ribozymes as therapeutic agents for bladder cancer.
    Irie A; Kashani-Sabet M; Scanlon KJ; Uchida T; Baba S
    Mol Urol; 2000; 4(2):61-6. PubMed ID: 12006244
    [TBL] [Abstract][Full Text] [Related]  

  • 59. International conference on Nucleic Acid Medical Applications, NAMA conference.
    Bradley MO; Alul RH; Bhan P
    Antisense Res Dev; 1993; 3(2):225-32. PubMed ID: 8400806
    [No Abstract]   [Full Text] [Related]  

  • 60. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
    J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.